Sign In

Sam Banister

Medicinal chemist - Biotech entrepreneur - Skydiver

Sam Banister is the co-founder and Chief Scientific Officer at Psylo, an Australian biotech company developing next-generation psychedelic medicines for treating mental health disorders.12 He has a strong background in scientific research, with a Ph.D. in Medicinal Chemistry from the University of Sydney and postdoctoral experience at Stanford University.3

Banister's career includes roles as a Postdoctoral Research Associate at the University of Sydney, Research Scientist at Stanford University, and Team Leader in Medicinal Chemistry at the Brain and Mind Centre.3 His research focuses on designing new methods for brain imaging and developing neurological and neuropsychiatric drugs for conditions such as ALS, depression, pain, and substance use disorders.4

At Psylo, Banister leads the development of different classes of pharmaceutical psychedelics, focusing on the deregulation of serotonin signaling systems in the body.1 He became interested in drug development and psychedelics at a young age, inspired by figures like Albert Hoffman and Timothy Leary.1

Banister's LinkedIn username is sambanister.1

Highlights

Feb 5 · linkedin

What does Therapeutic Goods Administration's rescheduling of MDMA and psilocybin mean for Psylo, Emyria (ASX:EMD), Reset Mind Sciences , and the emerging psychedelics industry?

Insights from Michael Winlo, Shaun Duffy, 🧪 Joshua Ismin, and Tenmile 's Steve Burnell.

Related Questions

What inspired Sam Banister to transition from academia to the private sector?
How did Sam Banister's early interests in psychedelics influence his career path?
What are the unique classes of drugs Psylo is developing for mental health treatment?
How does Psylo's approach to serotonin signaling systems differ from other biotech companies?
What challenges did Sam Banister face when starting Psylo?
Sam Banister
Sam Banister, photo 1
Sam Banister, photo 2
Add to my network

Location

Greater Sydney Area